SAVA - Cassava Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1900
+0.0800 (+7.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1100
Open1.1000
Bid1.1400 x 3200
Ask1.2000 x 1200
Day's Range1.1000 - 1.2171
52 Week Range0.2200 - 10.1500
Volume281,552
Avg. Volume120,953
Market Cap20.491M
Beta (3Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-0.4320
Earnings DateAug 8, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-13
1y Target Est23.75
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Cassava Sciences Announces New Website Launch

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com.  Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed.

  • GuruFocus.com24 days ago

    Weekly CFO Buys Highlight

    Insiders invest in Vaalco Energy, Dasan Zhone Solutions and Cassava Sciences

  • Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings
    Simply Wall St.last month

    Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswire2 months ago

    Cassava Sciences Reports First Quarter 2019 Financial Results

    AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.

  • GlobeNewswire2 months ago

    Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimer’s Disease

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease.  Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).